title: Infliximab therapy in two cases of severe neurotuberculosis paradoxical reaction.
authors: sophia@nus.edu.sg.
authors: James S
authors: JS
authors: Molton
authors: Paul J
authors: PJ
authors: Huggan
authors: Sophia
authors: S
authors: Archuleta
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000069285:Infliximab; D007538:Isoniazid / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D016862:Tuberculoma, Intracranial / Q000188:drug therapy*; D014390:Tuberculosis, Meningeal / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000995:Antitubercular Agents; D014409:Tumor Necrosis Factor-alpha; D011718:Pyrazinamide; D003907:Dexamethasone; D004977:Ethambutol; D011239:Prednisolone; D000069285:Infliximab; D007538:Isoniazid; D012293:Rifampin